The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Eisai Co Ltd in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Eisai Co Ltd.
A simulation model estimated lecanemab to potentially slow the rate of disease progression
The two companies will work on developing a drug for endometrial, ovarian, lung and breast cancers
The cost-effectiveness watchdog has now backed the thyroid cancer treatment
Issues draft guidance recommending against second-line use in breast cancer
Collaborates with Japanese smartphone app network Mamorio on the new tool
Approved as a second-line combination treatment for advanced RCC
Will consider legal action to address the ‘unfair and inequitable situation’ for UK cancer patients
Appoints Paul Hawthorne and Beyham Zaim to its US subsidiary
The oncology treatment could now be approved in the US before the summer
BuysLiaoning TianYi Biological Pharmaceutical
Newcompany will begin operations in April 2016
Willhand over Research Triangle Park facility incapacity-sharing deal
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology